In recent news,
Sanofi has made significant advancements in diversifying its product pipeline. Recently, Vir closed an exclusive agreement with Sanofi, granting them right to a variety of potential clinical-stage T-cell engagers. Alongside this, Sanofi has also chosen to heavily invest in an insulin plant in Frankfurt to the sum of €1.3 billion, while also facing a legal battle with Sarepta over manufacturing patent infringement claims. In the earnings circuit, Novavax is said to be benefiting from its dealings with Sanofi. Adding to this, Sanofi’s immunological research gamble appears to be paying off, demonstrating clear growth and advancements. Furthermore, the French pharma giant is expanding its Global Capability Center (GCC) in Hyderabad, aiming to create 1,600 jobs by 2026. Nonetheless, Sanofi continues its legal battle against Sarepta over US-based gene therapy patents. Additionally, Sanofi is investing $1.4bn in insulin production in Germany whilst maintaining a robust sales goal for its RSV drug.
Overall, Sanofi is also heavily investing in a global centre in India, planning for workforce expansion, and pushing towards a strong digital transformation.
Sanofi News Analytics from Wed, 15 Nov 2023 13:59:02 GMT to Fri, 02 Aug 2024 22:11:54 GMT -
Rating 5
- Innovation 4
- Information 7
- Rumor -2
